Insulin degludec and icodec represent distinct pharmacokinetic strategies for basal insulin. Degludec achieves ultra-long action through multi-hexamer chain formation in subcutaneous tissue, while icodec leverages enhanced albumin binding and reduced receptor affinity for ultra-slow clearance. The fundamental difference is dosing frequency: daily versus weekly.
- Sequence: Human insulin with ThrB30 deletion and LysB29-acylated with hexadecanedioic acid via γ-Glu linker
- Modifications: Threonine B30 deletion, C-16 fatty diacid at B29 via glutamic acid spacer
- MW: ~6,100 Da (monomer)
- Charge at pH 7.4: −2
- Formulation: Liquid suspension (Tresiba), 100 U/mL or 200 U/mL
- Appearance: Clear, colorless solution
- Sequence: Human insulin with A21Gly, B3Thr→30Thr, B29Lys-myristoyl-C20 fatty diacid, B27Lys-O-methyl
- Modifications: Four amino acid substitutions plus C-20 fatty diacid at B29
- MW: ~6,300 Da
- Charge at pH 7.4: −2
- Formulation: Solution (Awiqli), 100 U/mL
- Appearance: Clear, colorless solution
- Subcutaneous depot: Injected at pH 4, neutralized to pH 7.4 in tissue, forming di-hexamers
- Hexamer chain assembly: Di-hexamers self-associate into long chains via zinc-mediated coordination
- Gradual dissociation: Hexamers → dimers → monomers (rate-limiting step)
- Albumin binding: Monomers bind albumin (>99% protein-bound)
- Slow release: Albumin-bound insulin releases slowly to target tissues
- Continuous absorption: Near-flat PK profile over 42+ hours
- Enhanced albumin binding: Myristoyl-C20 fatty diacid increases hydrophobic interaction
- Reduced receptor affinity: B27 O-methyl modification slows IR binding kinetics
- Increased hydrodynamic radius: Slower renal filtration
- Ultra-slow clearance: Half-life ~196 hours (8.2 days)
- Continuous absorption: Near-flat PK profile over 7+ days
| Parameter | Insulin Degludec | Icodec |
|---|
| Half-life | ~25 hours | ~196 hours |
| T_max | 9–12 hours | 16–18 hours |
| Duration of action | 42+ hours | 7+ days |
| Steady state | 3–4 days | 5–7 weeks |
| Peak-to-trough ratio | ~1.3 | ~1.1 |
| Albumin binding | >99% | >99% |
| Dosing frequency | Once daily | Once weekly |
| Injection volume (50 U) | 0.5 mL (U-100) | 0.5 mL |
| Parameter | Insulin Degludec | Icodec |
|---|
| HbA1c reduction | −1.0 to −1.5% | −1.0 to −1.5% |
| Fasting glucose reduction | 40–60 mg/dL | 40–60 mg/dL |
| Time in range (CGM) | 70–80% | 70–80% |
| Glycemic variability | Low | Very low |
| Parameter | Insulin Degludec | Icodec |
|---|
| Overall hypoglycemia | 15–20% | 15–20% |
| Nocturnal hypoglycemia | 3–5% | 2–4% |
| Severe hypoglycemia | 1–2% | 1–2% |
| Level 2 (<54 mg/dL) | 5–10% | 5–10% |
- Starting dose: 10 U once daily or 0.1–0.2 U/kg
- Titration: Adjust by 2 U every 3–4 days
- Target fasting glucose: 80–130 mg/dL
- Maximum daily dose: 40–50 U (varies by indication)
- Flexibility: Can vary injection time by up to 8 hours without efficacy loss
- Starting dose: 70 U once weekly or 1 U/kg/week
- Titration: Adjust by 10–20 U every 4–5 weeks
- Target fasting glucose: 80–130 mg/dL
- Maximum weekly dose: 280 U (varies by indication)
- Flexibility: Fixed day of week; can shift by 1–2 days if needed
- DEVOTE: Cardiovascular safety — non-inferior to glargine U-100 for MACE
- SWITCH 1/2: Significantly lower hypoglycemia vs glargine U-100 (both overall and nocturnal)
- BEGIN: Non-inferior HbA1c reduction vs glargine U-100
- ONWARDS 1: Non-inferior HbA1c reduction vs degludec; lower overall hypoglycemia
- ONWARDS 2: Superior HbA1c reduction vs insulin glargine U-100
- ONWARDS 3: Lower hypoglycemia vs basal-bolus regimen
- ONWARDS 4: Comparable efficacy to basal-bolus in hospitalized patients
- Daily dosing already established
- Need for flexible injection timing
- High dose requirements (>100 U/day — 200 U/mL concentration available)
- Transition from other basal insulins
- Pediatric use (approved from 1 year)
- Needle phobia or injection burden concerns
- Poor adherence to daily injections
- Stable, predictable weekly routine
- Transition from degludec or glargine
- Adult patients only (not approved for pediatric)
| Effect | Degludec | Icodec |
|---|
| Injection site reactions | 2–5% | 2–5% |
| Hypoglycemia | 15–20% | 15–20% |
| Weight gain | 1–3 kg | 1–3 kg |
| Lipodystrophy | Rare | Rare |
| Allergic reactions | Very rare | Very rare |
Degludec: 200 U/mL formulation requires careful dose verification; higher concentration increases error risk.
Icodec: Weekly dosing means slower dose adjustment if hypoglycemia occurs; 5–7 week steady state delays optimization.
| Factor | Degludec | Icodec |
|---|
| Dosing frequency | 365 injections/year | 52 injections/year |
| Dose flexibility | ±8 hours | Fixed day |
| Time to steady state | 3–4 days | 5–7 weeks |
| Dose adjustment speed | Every 3–4 days | Every 4–5 weeks |
| Pen device | FlexTouch (disposable) | PushClick (reusable) |
| Storage (open) | 28 days (room temp) | 8 weeks (room temp) |
| Storage (closed) | 24 months (2–8°C) | 24 months (2–8°C) |
| Factor | Degludec | Icodec |
|---|
| Annual cost (US) | $4,000–6,000 | $4,000–6,000 |
| Insurance coverage | Widely covered | Expanding coverage |
| Biosimilar availability | Expected 2024+ | None |
| Injection supplies | Higher (daily) | Lower (weekly) |
Insulin degludec and icodec both achieve near-flat basal insulin profiles, but differ fundamentally in dosing frequency. Degludec offers flexibility with ±8 hours injection timing and 3–4 day steady state. Icodec reduces injection burden to 52/year but requires 5–7 weeks to reach steady state and offers limited titration flexibility. Both achieve comparable HbA1c reduction and hypoglycemia rates. The choice depends on patient preference, adherence patterns, and clinical need for dose adjustment speed.
